ALKS Q3 2023 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$381M+51.0% YoY

Gross Profit

$319M83.9% margin

Operating Income

$89M23.4% margin

Net Income

$48M12.5% margin

EPS (Diluted)

$0.28

QoQ Revenue Growth

-38.3%

Cash Flow

Operating Cash Flow

$100M

Free Cash Flow

$85M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$924M

Stockholders' Equity

$1.4B

Cash & Equivalents

$648M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$381M	$252M	+51.0%
Gross Profit	$319M	$202M	+58.3%
Operating Income	$89M	-$61M	+247.1%
Net Income	$48M	-$64M	+174.7%

Revenue Segments

Manufacturing Revenue

$41M100%